

Saudi Arabia

Population 2015

32 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.66 (0.21–1.4)	2.1 (0.66–4.3)
Mortality (HIV+TB only)	0.018 (<0.01–0.09)	0.06 (0–0.28)
Incidence (includes HIV+TB)	3.8 (3.3–4.4)	12 (10–14)
Incidence (HIV+TB only)	0.14 (0.11–0.16)	0.43 (0.36–0.51)
Incidence (MDR/RR-TB)**	0.15 (0.12–0.18)	0.48 (0.38–0.57)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.17 (0.11–0.23)	1.1 (0.66–1.5)	1.3 (0.77–1.7)
Males	0.13 (0.087–0.17)	2.5 (1.9–3)	2.6 (2–3.2)
Total	0.3 (0.22–0.38)	3.5 (3.2–3.9)	3.8 (3.3–4.4)

TB case notifications, 2015	
Total cases notified	3 464
Total new and relapse	3 346
- % tested with rapid diagnostics at time of diagnosis	23%
- % with known HIV status	51%
- % pulmonary	76%
- % bacteriologically confirmed among pulmonary	84%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.18 (0.06–0.37)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	69	4%
- on antiretroviral therapy		

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			110 (91–130)
Estimated % of TB cases with MDR/RR-TB	2.6% (2–3.2)	20% (16–25)	
% notified tested for rifampicin resistance	34%	36%	1 186
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 45, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 45, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	62%	3 248
Previously treated cases, excluding relapse, registered in 2014	33%	88
HIV-positive TB cases, all types, registered in 2014	27%	63
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	6%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB